Patents Assigned to Merck Serono Biodevelopment
  • Patent number: 8143024
    Abstract: The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia trachomatis, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the Chlamydia trachomatis genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Chlamydia trachomatis infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: March 27, 2012
    Assignee: Merck Serono Biodevelopment
    Inventors: Rémy Griffais, Susan K. Hoiseth, Robert J. Zagursky, Benjamin J. Metcalf, Joel A. Peek, Banumathi Sankaran, Leah D. Fletcher
  • Patent number: 7998671
    Abstract: The present invention is directed to BAP28 polypeptides. BAP28 cDNA sequences encoding BAP28 polypeptides, to the genomic DNA sequence of the BAP28 gene as well as to regulatory regions located at the 5?- and 3?-ends of the BAP28 coding region. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the BAP28 gene useful in genetic analysis. The invention concerns an association of the BAP28-related biallelic markers with prostate cancer. Therefore, the invention contemplates the diagnostic and treatment methods of prostate cancer.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: August 16, 2011
    Assignee: Merck Serono Biodevelopment
    Inventors: Caroline Barry, Lydie Bougueleret, Ilya Chumakov, Annick Cohen-Akenine